Register now to learn about a new option for relapsed or refractory follicular lymphoma

General Discussions

Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma

By Jessica Hergert
General Discussions - Discussions
23 replies
CAR T-cell therapy is poised to transform the treatment paradigm of relapsed/refractory multiple myeloma now that multiple products are exhibiting high and complete response (CR) rates, said Faiz Anwer, MD, who added that further research may improve safety, prolong responses, and provide insight into resistance mechanisms. 

“Due to the combination of specificity and cytotoxicity, we are seeing very high overall response rates [with CAR T-cell therapy],” said Anwer. “These response rates are variable, but in the range of 80% to 100%. The majority of these responses are very deep, [with most] patients achieving minimal residual disease [MRD] negativity. Achieving MRD negativity is the best outcome that we can expect from any therapy.”

On September 22, 2020, the FDA granted a priority review designation to a biologics license application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) in patients with multiple myeloma who have received at least 2 previous therapies, including a proteasome inhibitor (PI), an immunomodulatory (IMiD) agent, and an anti-CD38 antibody.

Data from the phase 2 KarMMa trial, which led to the BLA submission, showed that ide-cel induced a response in 73% of patients with heavily pretreated, relapsed/refractory disease. Moreover, the CR rate was 33% with the product.

In an interview with Oncology Nursing News' sister publication, OncLive, during the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, a member of the Hematopoietic and Immune Cancer Biology Program at Case Comprehensive Cancer Center, and an associate professor in the Department of Medicine at the School of Medicine at Case Western Reserve University, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need. 

OncLive®: What are some of the advantages of CAR T-cell therapy in multiple myeloma? 

Anwer: CAR T-cell therapy has some unique advantages compared with other treatments. CAR T-cell therapy has the advantage of targeted specificity, which we see with many monoclonal antibodies. At the same time, because [CAR T-cell therapy is] a cell-based, specifically T-cell–based, therapy, we see the cytotoxic advantage of T cells. 

[Patients] receive a single infusion of CAR T cells. Many of these patients respond very quickly and maintain these responses for a long duration of time. Those longer lasting responses can [persist] for more than 1 year, and in many cases, more than a couple of years.

The benefit is that no maintenance therapy is required at this time. However, in the future, we can postulate that combination therapies will emerge, and a maintenance strategy will be introduced to improve the duration of response. 

The CAR T-cell products [that are used in multiple myeloma] are safer compared with some of the other products that were used in the beginning in other diseases. In terms of safety, we are seeing less central nervous system [CNS] toxicity. The intensity of cytokine release syndrome [CRS], which is another major toxicity [associated with] CAR T-cell therapy, is actually less in multiple myeloma [than in other hematologic malignancies].

Beyond BCMA, what other potential targets are under investigation?  

At this point, many targets are emerging aside from BCMA. We see a role for CD38 as a target as it is being explored with naked antibodies, such as daratumumab [Darzalex], in combination with antibody-drug conjugates. 

In addition, GPRC5D is another target. CD19 has also been explored as another target. More excitement will come from dual targeting where either 2 different types of CAR T-cell therapies can be used, or 1 CAR T-cell product can be configured to achieve dual targeting of the myeloma cell.

How have data from the CARTITUDE-1, LEGEND-2, and KarMMa trials solidified a role for CAR T-cell therapy in multiple myeloma? 

We have more data from the phase 1 and 2 setting. That is where initial CAR T-cell therapy data were very exciting because [the studies] showed quicker, deeper responses with longer durations of response. They provided us with the initial insight into what type of adverse effects [AEs] we are going to face while using the CAR T-cell technology in multiple myeloma, as well as how to best manage [those AEs].

We will continue to see new products and new techniques emerge, which will likely [mitigate] some of these challenges. [Moreover], improved products and techniques will likely resolve some of these AEs that can be [severe]. 

In terms of responses for the products that are more advanced, [the data with] JNJ-4528/LCAR-B38M are exciting in terms of overall responses, which were reported in the range of 100%, with CRs approaching almost 70%. The MRD-negativity rate was also 100%.

At the same time, data from the KarMMa trial showed that ide-cel [induced] very high objective responses above 70%. The progression-free survival is measured in months and [CR rates] are also impressive with ide-cel.

What is your approach to managing patients who develop CRS or CNS toxicities after CAR T-cell infusion? 

We have learned through the treatment of other diseases, such as leukemia and lymphoma, that the challenges [that manifest with] CAR T-cell therapy are CRS and CNS toxicity. We’re facing the same challenges in multiple myeloma. 

Patients [treated with CAR T-cell therapy] are typically monitored very closely with daily assessments to [identify] these AEs. If [a patient] starts developing [signs of] CNS toxicity, such as confusion, seizures, fever, and low blood pressure, they are managed according to the defined protocol. Each individual center may have carved out their own unique approach to managing these toxicities, but typically, patients require close monitoring of fluid balance, antibiotics, and judicious use of steroids and tocilizumab [Actemra].

What strategies should be implemented to reduce CRS and CNS toxicities?

We need to have a comprehensive infection prophylaxis strategy—a vaccination strategy—to prevent any long-term issues with infections. The therapy has to be integrated safety with the existing myeloma treatment [before patients receive] CAR T-cell therapy. 

Where should future research efforts focus with regard to the remaining challenges of CAR T-cell therapy?

At this time, we can potentially count more than 50 open trials in the pipeline that will open for enrollment in the near future. The issues that we want to address include how to continue to make CAR T-cell therapy safe and effective, and to [prolong] responses.

Also, we want to look at the efficacy of repeat infusion and [identify] the optimal combination therapy with CAR T-cell therapy and other existing treatment. [Combinations] may be in the space of an IMiD, a PI, or a targeted antibody.

We also need to figure out how to overcome resistance, which ultimately [occurs] after an infusion while the CAR T cells are still in the body. What is the escape mechanism and how do we address it? Do we need to [implement] a dual-targeting approach? We may need to combine a multi-agent chemotherapy approach to improve upon the efficacy of the product and overcome the resistance.

At the same time, we need to continue to look at novel markers to improve responses and identify markers that we can potentially use to predict outcome. Is there a particular product for which a patient is going to respond better compared with another product? These individualized approaches where we can use unique CAR T-cell products for unique patients is where the future should be headed.

Could CAR T-cell therapy have utility in earlier lines of treatment? 

At this point, CAR T-cell therapy is being testing in heavily pretreated patient populations, but as we get more comfortable and see more data, we need to move CAR T up into the first- or second-relapse settings. In certain cases, it is absolutely justified to start testing CAR T-cell therapy in the frontline setting for patients who have high-risk multiple myeloma, patients who have primary resistance to frontline therapy, and patients who have plasma cell leukemias.

Looking to the future, how could the introduction of off-the-shelf, allogeneic CAR T-cell products provide additional benefit to patients?

The major benefit of off-the-shelf CAR T-cell therapy products will be the time-to-treatment once we make a decision that the patient has relapsed/refractory disease [and requires CAR T-cell therapy].

At this time, we also face the challenge of T-cell collection failure in heavily pretreated patients who have cytopenias or have received heavy doses of radiation therapy to their bone marrow. In those cases, it may be difficult to collect T cells. Therefore, off-the-shelf products [would be advantageous in those cases.

One example [of an off-the-shelf product] is ALLO-715, which is in phase 1 testing at this time. We [may be able] to quickly infuse the cells to achieve effective disease control.

Could you speak to the importance of enrolling patients onto clinical trials?

I encourage patients to participate in clinical trials to support new drug development. That is how we can continue to see further advancements in the field. That is how we have arrived to where we are now, and that is how we are going to [make even more advances] in the future. We need to continue to support research and drug development. 

1. US Food and Drug Administration (FDA) accepts for priority review Bristol Myers Squibb and bluebird bio application for anti-BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel; bb2121). News release. Bristol Myers Squibb and bluebird bio, Inc. September 22, 2020. Accessed October 27, 2020.
2. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. J Clin Oncol. 2020;38(suppl 15):8503. doi:10.1200/JCO.2020.38.15_suppl.8503

This article was originally published on OncLive as, "High Response Rates Heighten Excitement With CAR T-Cell Therapy in Multiple Myeloma."
By laramarry
Nov 04, 2020 12:38:38 am
If you want to buy glasses that protect your eyes from blue light, here you can buy your favorite glasses online such a, 1)Clip on glasses
By K13
Nov 04, 2020 1:24:22 am
I'm very grateful to the author, this really changed my thought. I'm looking forward to acknowledge this website as one of the best for new information. pepper potts iron man suit
By ezgosak9
Nov 04, 2020 2:37:18 am
Hi, thanks for your nice blog. It's really detailed and helpful instagram font
By annajenner
Nov 04, 2020 11:22:28 am
Hi! thanks for your post! I have an idea to develop my custom application, but I don't know from where to start. So now I am searching for quality android app development services. Hope to find such company in the nearest future.
By Jessica Campos
Nov 05, 2020 3:01:49 am
Antivirus software is important to install in our computers. It is said that roofing companies Odessa TX recommended best antivirus software. We can protect our important files from virus. Antivirus software can automatically remove virus from our computer and can protect our files.
By Joker slot
Nov 07, 2020 4:36:00 am
You write well I really like what you write. I would like to recommend my website. If it doesn't bother much, please It is the most modern casino and also has a 24-hour automatic deposit-withdrawal system if you are looking for an online casino website. This website is the number 1 site in the casino field, with many games for you to choose from joker123 ????? saxygame
By ...
Nov 09, 2020 5:50:21 am;jsessionid=gq4dl6xz7nzt1efttfh8bqwoo?,190453/id,111937/Genuine-Conditions-Of-Writing-An-Exploratory-Essay.html,190453/id,111938/Arrangement-Of-Essay-Paragraphs-According-To-Author-References.html,190453/id,111941/Tips-To-Write-A-Unique-Persuasive-Essay.html,190453/id,111942/Organize-Essay-Body-Paragraphs-According-To-Explanation.html,190453/id,111940/Anticipatory-Set-Of-An-Essay-Writing-With-Examples.html;area=forumprofile;u=951107;u=32862;u=42151;area=summary;u=1021436***
By bellarose
Nov 11, 2020 3:56:20 am
Jump a deal site is basically online store site and i inform you to all please visit this site. Because i visit this site i order my phone and i has a good experience to buy a phone
By jiraporn66
Nov 13, 2020 5:15:32 am
Hi, it's the first time I comment everywhere when reading this post, I think I can still make a comment because it's a post with interesting textual content.Your slot post will be very helpful in getting the correct weight loss advice. Share beautiful photos of the same type. Thanks for sharing these tips. I'll try it at home Update this simple tip.
By Jessica Campos
Nov 13, 2020 11:12:54 am
Girls have more mental depression than boys. They need to face more pain than others. Now we can find solution of Menstrual Cramps to get rid from different pains. It seems that akinator appreciate those who are working on this and giving tips for this solution.
By ...
Nov 14, 2020 5:25:45 am,20,20,20,20,20,20
By Danny374
Nov 14, 2020 12:47:19 pm
It is really good to see. T-cell therapy is really difficult, as it needs to recognize the receptor to work on it. You have to work on the new virus. It is hampering the whole man-made system of the world. You have to wear washable isolation gowns Canada to be safe from this virus.
By Jey
Nov 15, 2020 8:21:02 am
Nice, great info, get the Punjabi quotes to motivate you
By urdu poetry
Nov 16, 2020 7:00:17 am
Promising Response Rates Build Excitement for CAR T-Cell Therapy in ... T-cell therapy may change the treatment paradigm for relapsed/refractory myeloma. by urdu poetry
By urdu poetry
Nov 16, 2020 7:01:17 am
T-cell therapies are a promising approach for treating MM, with a mechanism of ... One of the main rationales for current efforts to develop CAR-T therapies for MM is the ... daratumumab had a 36% response rate in patients with refractory myeloma. ... The most exciting aspect of CAR-T therapy for MM is that it offers a novel ... by buy instagram followers uk
By michellejenkins
Nov 16, 2020 9:03:06 am
This is great news! Our team at Concrete Builders in Syracuse wish you more achievements like this one here.
By ...
Nov 18, 2020 5:11:29 am,190453/id,111937/Genuine-Conditions-Of-Writing-An-Exploratory-Essay.html,190453/id,111938/Arrangement-Of-Essay-Paragraphs-According-To-Author-References.html,190453/id,111941/Tips-To-Write-A-Unique-Persuasive-Essay.html,190453/id,111942/Organize-Essay-Body-Paragraphs-According-To-Explanation.html,190453/id,111940/Anticipatory-Set-Of-An-Essay-Writing-With-Examples.html;area=forumprofile;u=951107;u=32862;u=42151;area=summary;u=1021436***!/
By umarkhan
Nov 20, 2020 6:53:43 am
Your content is nothing short of brilliant in many ways. I think this is engaging and eye-opening material. Thank you so much for caring about your content and your readers. ooglidcorrectie
By major365
Nov 21, 2020 8:31:14 am
???? ????? ????? ?? ???? ?????? ??????? ?????? ?365????? ?????? ??????? ??? ?????? ??. ???? ????? ?? ????? ???????. ??????? ?? ???? ?? ?????. ????? ??????? ?????? ???????? ??????? ?????? ??????? ????? ????? ??????? ????? ???????? ???????? ???????? ?????? ??????? ?????? ???????? ????
By joandavis
Nov 30, 2020 8:00:17 am
There are reliable Case Study Assignment Services that are very popular for students in search of business case study writing services and case study assignment help.
By jamse
Nov 30, 2020 10:54:13 am
Women's Fashion Clothes , Shoes , Jewelry , Watches prtya Online Store
By ...
Nov 30, 2020 2:39:59 pm

Signs of a Successful Small Business Owner


When starting a new business, there are numerous signs that can indicate whether you're succeeding as an entrepreneur or aren't. A small business can be risky. This is particularly true if you specialize in a niche that bigger companies already excel in. However, if you display some particular qualities, it's a sign that you're doing a good job to stay afloat.

That's because small business owner who have a positive attitude towards success are the most likely to get a taste of it than his counterparts "SKIP BAYLESS". Their counterparts focus only on stability and nothing more. While business success has a lot to do with your initial idea and how you build upon that idea, it still depends on your personality and capabilities. Here are the few signs of a successful small business owner that you should develop as part of your personality.

You Like To Form Collaborations

Most successful entrepreneurs display this common trait. They understand the importance of having a well-connected network in the business world. Nevertheless, just like in every other change, collaboration needs to start from within your business. This means you'll need to start delegating tasks effectively. Another crucial part of this is building good relationships with everyone on your team. This includes your employees and suppliers.

Of course, you also need to establish a position in the network of small businesses. It's unwise to act alone without any partners. You needn't form friendly relationships with your competitors. However, at the least, you should be on good terms with other small businesses that complement yours. By obtaining a position in the community of other businesses, you'll be able to create new opportunities that can benefit others. Moreover, others can do the same for you. What results is a beneficial support system that allows all members to rely on one another.

You Have Your Eyes Set on the Future

You never know what the future holds, especially if it's for something as volatile as a new startup business. That's why successful entrepreneurs share a common characteristic of looking towards long-term future goals.

Some struggle to stay afloat amidst a rocky economic climate, and such desperate conditions can lead to business owners not looking farther than the near future. Such thoughts are understandable, but think of it this way; acting upon well-structured long-term goals at the same time as day-to-day tasks can ensure far more than financial stability and simple peace of mind.

Your Leverage the Benefit of Technology

Nowadays, when it comes to operating a small business, it all comes down to incorporating the use of technology, whether in marketing, management, or everything else. Technology and software have made it easier for entrepreneurs and small business owner to meet their goals, and now with services like Google AdWords and personal assistants, functions have become much more streamlined than ever before.

Take websites, for instance, they're a business' online identity and that's where most potential customers will go to check whether your brand is legitimate or not. Then comes social media, which is a useful marketing tactic that produces results without requiring you to spend too much of your ad revenue. Then there are other business-related applications like customer support live chat software, fixed responses for keywords and budgeting tools that boost your productivity so you can focus on product quality.

You Love to Learn

You're never ready to run a business until you're prepared to improve yourself by learning from others. You may be determined to make it through with a method involving trial and error, but that costs precious resources; you need to start learning from others' success and failures. Data is the most powerful weapon that a business can possess because it helps you discover trends and important details.

If you aim to learn about what strategies lead to profitable ideas and which ones are just downright terrible, you'll be able to devise a solution of your own. The best way to fulfill your curiosity is to read and look into insights regarding management, marketing, customer satisfaction, and product quality. Archives can provide you with numerous researches and surveys conducted by different companies. While it isn't necessary that the results apply to your business, you're still bound to learn something.

You Don't Just Think; You Act

While we're at it, we might as well establish that being a smart business owner doesn't mean that you'll never have to take risks; it's merely the ability to take risks with confidence. "SKIP BAYLESS Biography" One sign that your business will soon see the light of success is that you don't just think, you also act when the time is right. This sign is associated with the confident ability to make good decisions, even if they're risky.

It's true that before you put any plan into action, you need to examine it carefully all the way through. However, if you become stuck on the evaluating stage, you'll miss your chance to implement your idea. That's why you should have some faith in yourself and build confidence in your abilities to make a good decision.

By Yonsyr
Dec 01, 2020 10:25:15 am This is exactly the service that has become my accompanying study assistant throughout all my years of study at the university, and in many ways, success depends on it.
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.